VivoSeq
Oncology

Non-Malignant Disorders

0

Pipeline Programs↗

6

Active Trials↗

0

Companies Involved↗

Non-malignant Disorders is an early-stage landscape with 0 programs across 0 companies.

Intelligence

Pipeline Metrics

Competitive Density

21/100

Pipeline Velocity

0/100

Mech. Concentration

N/A

Completion Rate

50/100

Attrition Rate

13/100

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

8

clinical trials

Recruiting5 · 63%
Active, not recruiting1 · 13%
Completed1 · 13%
Terminated1 · 13%

Clinical Trials

Trial Activity

8 trials

Data Collection Study of Patients With Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT With RIC
Recruiting·—·N/A·NCT04528355·50 enrolled
Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Thiotepa in Treating Patients With Non-malignant Disorders
Recruiting·FFred Hutchinson Cancer Center·Phase 2·NCT03980769·40 enrolled
Cord Blood Transplant in Children and Young Adults With Blood Cancers and Non-malignant Disorders
Recruiting·MMemorial Sloan Kettering Cancer Center·Phase 2·NCT04644016·31 enrolled
Reduced Intensity Conditioning for Non-Malignant Disorders Undergoing UCBT, BMT or PBSCT
Recruiting·—·Phase 2·NCT01962415·100 enrolled
Reduced Intensity Conditioning and Familial HLA-Mismatched BMT for Non-Malignant Disorders
Recruiting·WWashington University School of Medicine·Phase 1/2·NCT03128996·29 enrolled
Reduced Intensity Conditioning (RIC) Regimen for Patients With Non-malignant Disorders
Active, not recruiting·—·Phase 2·NCT01050855·75 enrolled
Reduced Intensity Conditioning for Umbilical Cord Blood Transplant in Pediatric Patients With Non-Malignant Disorders
Completed·—·Phase 1·NCT00744692·22 enrolled
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
Terminated·—·Phase 1/2·NCT00801931·1 enrolled

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)